By using a UK cross-sectional cohort of adalimumab-treated RA patients, followed by validation in a European prospective cohort, we have identified that a reduced frequency of SIRPα/β+memory B cells prior to adalimumab treatment, compared to ADA− RA patients, allows the prediction ADA development in RA patients. Here, SIRPA is linked to rheumatoid arthritis.